Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.45 |
| ▸ | WDR5 | P61964 | 1/20 | 0.44 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23152216 | 0.91 | CTSD (0.50) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL10935027 | 0.90 | ALDH1A1 (0.52) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL4799007 | 0.88 | ALDH1A1 (0.50) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL2420501 | 0.88 | ALDH1A1 (0.50) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL503962 | 0.87 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL30393029 | 0.87 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL6562825 | 0.87 | ALDH1A1 (0.66) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL3629367 | 0.87 | RAB9A (0.48) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Hydrochloric Acid SCHEMBL1037379 | 0.85 | ALDH1A1 (0.60) | ALDH1A1KDM4EHSD17B10CTSDRAB9A | |
| SCHEMBL4345297 | 0.85 | NPC1 (0.60) | ALDH1A1KDM4EHPGDHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197654-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF A PRODUCT WHICH ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF PARKINSON'S DISEASE | AVENTIS PHARMA S.A. (FR) | 2007-08-23 | — | — | US | disclosed |
| US-7217705-B2 | Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | AVENTIS PHARMA S.A. (FR) | 2007-05-15 | — | — | US | disclosed |
| US-20040209861-A1 | Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | AVENTIS PHARMA S.A. (FR) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209861-A1 | Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | CNR1, CNR2, GPR18 | ALDH1A1 2669/4885KDM4E 2980/4885HPGD 941/4885 |
| US-20070197654-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF A PRODUCT WHICH ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF PARKINSON'S DISEASE | CNR1, CNR2, GPR18 | ALDH1A1 3094/4885KDM4E 3157/4885HPGD 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.